MedPath

A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance

Not Applicable
Completed
Conditions
Hormone Imbalance
Polycystic Ovary Syndrome
Interventions
Dietary Supplement: Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement
Registration Number
NCT06158932
Lead Sponsor
Optify
Brief Summary

This is a virtual single group study that will last 12 weeks. 40 female participants will take 4 capsules of the Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement per day. Questionnaires will be completed at Baseline, Week 4, Week 8 and Week 12. Participants will also provide a waist circumference measurement at Baseline and Week 12.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Women aged between 18 - 55
  • BMI less than 35
  • Self-reported symptoms of PCOS like irregular periods, excessive hair growth, weight gain, oily skin, or acne
  • Self-reported concerns around irregular menstrual cycles and ovulation, mood swings, stress, irritability, and low energy
  • Self-reported concerns with hormonal skin issues
  • Has access to a tape measure for waist measurement
  • Generally healthy - don't live with any uncontrolled chronic disease
Exclusion Criteria
  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
  • Anyone with known severe allergic reactions
  • Anyone who is pregnant or breastfeeding
  • Unwilling to follow the study protocol

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Myo Inositol and D-Chiro Inositol SupplementOptify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplementParticipants must take 4 capsules per day, with water. The product should be taken with the last meal of the day.
Primary Outcome Measures
NameTimeMethod
Changes in menstrual cycle regularity. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires with participants reporting menstrual cycle occurrence and regularity during the trial.

Changes in hormonal skin issues. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in excessive body hair or facial hair. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in severity of menstrual cramps. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Secondary Outcome Measures
NameTimeMethod
Changes in sleep quality. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in energy. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in mood. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in stress. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Changes in food cravings. [Timeframe: Baseline to Week 12]12 weeks

Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.

Trial Locations

Locations (1)

Citruslabs

🇺🇸

Santa Monica, California, United States

© Copyright 2025. All Rights Reserved by MedPath